Display options
Cite
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95doi: 10.1177/1759720X15591801.
Eder, L., & Gladman, D. D. (2015). Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Therapeutic advances in musculoskeletal disease, 7(5), 187-95. https://doi.org/10.1177/1759720X15591801
Eder, Lihi, and Gladman, Dafna D. "Atherosclerosis in psoriatic disease: latest evidence and clinical implications." Therapeutic advances in musculoskeletal disease vol. 7,5 (2015): 187-95. doi: https://doi.org/10.1177/1759720X15591801
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015 Oct;7(5):187-95. doi: 10.1177/1759720X15591801. PMID: 26425147; PMCID: PMC4572363.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Musculoskelet Dis. 2015 Oct;7(5):187-95. doi: 10.1177/1759720X15591801.

Atherosclerosis in psoriatic disease: latest evidence and clinical implications.

Therapeutic advances in musculoskeletal disease

Lihi Eder, Dafna D Gladman

Affiliations

  1. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  2. Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, Ontario, Canada M5T 2S8.

PMID: 26425147 PMCID: PMC4572363 DOI: 10.1177/1759720X15591801

Abstract

It is widely accepted that atherosclerosis is caused by chronic low-grade inflammation that results from an interaction between immune mechanisms and metabolic abnormalities within the vessel wall. Population-based studies have found an increased cardiovascular risk in patients with psoriasis and psoriatic arthritis (PsA). This risk is higher in patients with severe disease phenotypes, such as those with severe psoriasis and with musculoskeletal inflammation. Higher levels of inflammatory biomarkers also predict the development of clinical cardiovascular events in these patients. The effect of medications used for PsA on cardiovascular risk is limited to observational studies. Antitumor necrosis factor agents and methotrexate have been associated with reduced cardiovascular risk. These data highlight the importance of screening for cardiovascular risk factors in these patients.

Keywords: atherosclerosis; cardiovascular disease; inflammation; psoriatic arthritis

References

  1. Arteriosclerosis. 1986 Mar-Apr;6(2):131-8 - PubMed
  2. Semin Arthritis Rheum. 2007 Feb;36(4):203-9 - PubMed
  3. Ann Rheum Dis. 2010 Feb;69(2):325-31 - PubMed
  4. Br J Dermatol. 2013 Dec;169(6):1180-7 - PubMed
  5. J Clin Endocrinol Metab. 2011 Jan;96(1):E146-50 - PubMed
  6. Curr Atheroscler Rep. 2013 Jan;15(1):295 - PubMed
  7. Ann Rheum Dis. 2009 Jul;68(7):1131-5 - PubMed
  8. J Drugs Dermatol. 2014 Aug;13(8):932-4 - PubMed
  9. Ann Rheum Dis. 2015 Oct;74(10 ):1830-5 - PubMed
  10. Circulation. 2007 Oct 16;116(16):1832-44 - PubMed
  11. Arthritis Care Res (Hoboken). 2014 Jan;66(1):97-103 - PubMed
  12. JAMA. 2011 Aug 24;306(8):864-71 - PubMed
  13. Rheumatology (Oxford). 2010 Feb;49(2):295-307 - PubMed
  14. Rheumatol Int. 2015 Aug;35(8):1385-92 - PubMed
  15. Rheumatology (Oxford). 2014 Jun;53(6):1108-19 - PubMed
  16. Ann Rheum Dis. 2014 Nov;73(11):1990-6 - PubMed
  17. Ann Rheum Dis. 2012 Aug;71(8):1273-7 - PubMed
  18. J Am Acad Dermatol. 2012 Oct;67(4):796-8 - PubMed
  19. J Am Acad Dermatol. 2013 Dec;69(6):1014-24 - PubMed
  20. Am J Med. 2014 Dec;127(12):1148-53 - PubMed
  21. J Rheumatol. 2006 Nov;33(11):2167-72 - PubMed
  22. Arthritis Rheum. 2009 Oct 15;61(10 ):1373-8 - PubMed
  23. J Intern Med. 2011 Aug;270(2):147-57 - PubMed
  24. Exp Dermatol. 2011 Apr;20(4):303-7 - PubMed
  25. J Rheumatol. 2014 Nov;41(11):2315-22 - PubMed
  26. Arch Dermatol. 2005 Dec;141(12 ):1537-41 - PubMed
  27. Nat Med. 2011 Nov 07;17(11):1410-22 - PubMed
  28. Arthritis Rheum. 2008 Sep 15;59(9):1322-31 - PubMed
  29. J Invest Dermatol. 2014 Mar;134(3):635-42 - PubMed
  30. J Am Acad Dermatol. 2014 Jan;70(1):168-77 - PubMed
  31. Br J Dermatol. 2012 Apr;166(4):811-8 - PubMed
  32. Arch Dermatol. 2012 Jan;148(1):95-102 - PubMed
  33. Nat Med. 2011 Jul 07;17 (7):790-1 - PubMed
  34. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2658-68 - PubMed
  35. Int J Rheumatol. 2012;2012:714321 - PubMed
  36. Arthritis Rheum. 2007 Mar 15;57(2):287-93 - PubMed
  37. Arthritis Rheum. 2007 Mar;56(3):831-9 - PubMed
  38. Arthritis Care Res (Hoboken). 2011 Dec;63(12):1729-35 - PubMed
  39. Lancet. 2002 Apr 6;359(9313):1173-7 - PubMed
  40. Trans Am Clin Climatol Assoc. 2013;124:174-90 - PubMed
  41. J Invest Dermatol. 2013 Oct;133(10):2340-6 - PubMed
  42. Joint Bone Spine. 2014 Oct;81(5):421-5 - PubMed
  43. Ann Rheum Dis. 2013 Dec;72(12):1956-61 - PubMed
  44. N Engl J Med. 2005 Apr 21;352(16):1685-95 - PubMed
  45. Circulation. 2008 Jun 3;117(22):2919-27 - PubMed
  46. Ann Rheum Dis. 2011 Apr;70(4):705-6 - PubMed
  47. Int J Rheum Dis. 2016 Mar;19(3):300-4 - PubMed
  48. Ann Rheum Dis. 2015 May;74(5):813-7 - PubMed
  49. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7 - PubMed
  50. Rheumatology (Oxford). 2014 Feb;53(2):346-52 - PubMed
  51. Rheumatology (Oxford). 2012 Mar;51(3):552-6 - PubMed
  52. Br J Dermatol. 2013 Mar;168(3):486-95 - PubMed
  53. Cell. 2011 Apr 29;145(3):341-55 - PubMed
  54. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1128-34 - PubMed
  55. Arthritis Res Ther. 2014 Jul 30;16(4):R161 - PubMed
  56. Atherosclerosis. 2012 Sep;224(1):218-21 - PubMed
  57. Ann Rheum Dis. 2010 Dec;69(12):2114-7 - PubMed
  58. N Engl J Med. 2009 Jul 30;361(5):496-509 - PubMed
  59. Ann Rheum Dis. 2015 Feb;74(2):326-32 - PubMed
  60. Atherosclerosis. 2012 Sep;224(1):12-24 - PubMed
  61. Arthritis Rheum. 2012 Jun;64(6):1879-87 - PubMed
  62. J Am Acad Dermatol. 2005 Feb;52(2):262-7 - PubMed
  63. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1262-8 - PubMed

Publication Types